Treat Solid News Today

HanchorBio Received IND Approval of HCB101 Multi-Regional Clinical Trial By Taiwan FDA TAIPEI & SAN FRANCISCO, July 24, 2023 (Newswire.com) - HanchorBio Inc., a global clinical-stage biotechnology company...

HanchorBio Announces US IND Clearance for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies HanchorBio Received IND Clearance of HCB101 Multi-regional Clinical Trial By US FDA TAIPEI, TAIWAN and SAN FRANCISCO, ...

New studies highlight CAR-T therapy’s success in treating acute lymphoblastic leukemia and lymphoma.

Advancing BRILLIANCE trial of EDIT-101 for LCA10; clinical data expected by year-end RUBY trial of EDIT-301 for sickle cell disease active and recruiting Preclinical ocular data presented at ARVO supports in vivo gene editing $723 million as of March 31, 2021 CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the first quarter of 2021. “Our team is making ...

Published: May 05, 2021 Advancing BRILLIANCE trial of EDIT-101 for LCA10; clinical data expected by year-end RUBY trial of EDIT-301 for sickle cell disease active and recruiting Preclinical ocular data presented at ARVO supports in vivo gene editing $723 million as of March 31, 2021 CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the first quarter of 20...